Synergistic Minimally Invasive Surgery and Deferoxamine in ICH
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 240 participants.
Also called NCT07162363
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 240 participants
- Registry
-
NCT07162363
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07162363. Randomized; single masking; primary purpose treatment. Start 2026-03-01 (anticipated); primary completion 2028-12-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Synergistic Minimally Invasive Surgery and Deferoxamine in ICH
- Acronym
- SMAD
- Condition
- Intracerebral Hemorrhage
- Condition
- ICH - Intracerebral Hemorrhage
- Intervention (Procedure)
- Minimally Invasive surgery (MIS)
- Intervention (Drug)
- Deferoxamine
- Intervention (Other)
- Standard Medical Care (SMD)
- Lead sponsor
- University of Illinois Chicago
Record details
- Record id
cardio:ct-nct07162363- Content hash
9e10a92186a0e619c4328de7737f493dce70e2450f080e89b3012fa1317d3cbe